Ramón García-Sanz, MD, PhD
Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain
Research Interests: Hematological malignancies, clinical trials and biological studies in therapies for hodgkin’s lymphomas, Waldenström's macroglobulinemia and multiple myeloma
Ramón García-Sanz, MD, PhD, has been a consulting physician in hematology at the University Hospital of Salamanca, Spain, since 1994 and serves as a hematology researcher at the Center of Investigation in Cancer in Salamanca. He has also been Associated Professor of the University of Salamanca since 2007.
Dr. García-Sanz earned his MD in 1988 and his PhD in 1994 at the University of Salamanca. His thesis in multiple myeloma (MM) biology and prognostic factors was honored with the Thesis extraordinary award 1993-94. He pursued postdoctoral studies in molecular biology of lymphoproliferative disorders at Erasmus University of Rotterdam, The Netherlands.
In the field of hematological malignancies, Dr. García-Sanz has served as main investigator or co-investigator in clinical trials of therapies for hodgkin’s lymphomas, Waldenström's macroglobulinemia and multiple myeloma. His research interest also included biological studies in these diseases, including development of European standardization criteria in molecular biology and Waldenström’s Macroglobuilnemia.
Dr. García-Sanz has authored more than 400 original research articles and book chapters, as well as several publications in Spanish, with more than 25,000 references listed in scholar.google.es and an H index of 77. Dr. García-Sanz is one of the founders of the Spanish Myeloma Group (GEM/PETHEMA) and he is now the Main Coordinator of the Hodgkin’s Lymphoma Subcommittee of the Spanish Group of Lymphomas and Autologous Stem Cell Transplantation (GELTAMO), where he has focused one of his main topics of interest in clinical trials in Hodgkin’s Lymphoma, as well as Diagnostic Tools and Minimal Residual Disease Monitoring in Non-Hodgkin’s Lymphoma, Multiple Myeloma and Waldenström’s Macroglobulinemia. Finally, Dr. García-Sanz is currently the president of the Spanish Society of Hematology and Hemotherapy (SEHH).
Editorial Board
Terms of Appointment: June 2022 - May 2024